Abbott Rx For R&D Includes Tandem Drug/Biologic Development
Executive Summary
Developing biologics and drugs in tandem for the same target is one method Abbott is using to improve R&D productivity
You may also be interested in...
Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says
Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date
Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says
Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date
R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME
Pharmaceutical R&D execs estimate the cost of drug development to be $1.4 bil. per new molecular entity, Wyeth R&D President Robert Ruffolo, PhD, told an IBC conference in Boston Aug. 12